When PMN could get FDA promising

ProMIS Neurosciences' lead therapeutic candidate, PMN310, has already received FDA Fast Track designation for the treatment of Alzheimer's disease. This designation is intended to expedite the development and review of new drugs that address unmet medical needs, and it is a significant milestone in the regulatory process. While the FDA Fast Track designation is a promising development, it is important to note that PMN310 must still demonstrate safety and efficacy in larger trials before potential approval. ProMIS Neurosciences is currently conducting the PRECISE-AD Phase 1b trial, with interim data expected in Q2 2026 and final results in Q4 2026. The final results of the Phase 1b trial will be crucial in determining the safety and efficacy of PMN310, and they will be closely monitored by the FDA. In conclusion, while PMN310 has received FDA Fast Track designation, it is still in the clinical trial phase, and approval is not yet guaranteed. The company's progress in the ongoing Phase 1b trial and the final results of the trial will be key factors in determining when PMN310 could potentially receive FDA approval.